Anticoagulant and antiprotease effects of a novel heparinlike compound from shrimp (Penaeus brasiliensis) and its neutralization by heparinase I.
Heparin is usually obtained from mammalian organs, such as beef lung, beef mucosa, porcine mucosa, and sheep intestinal mucosa. Because of the increased use of heparin in the production of low-molecular-weight heparin (LMWH), there is a growing shortage of the raw material needed to produce LMWHs. A previous report described the structural features of a novel LMWH from the shrimp (Penaeus brasiliensis). In order to compare anticoagulant and antiprotease effects of this heparin, global anticoagulant tests, such as the prothrombin time, activated partial thromboplastin time, thrombin time, and Heptest, were used. Amidolytic anti-Xa and anti-IIa activities were also measured. The relative susceptibility of this heparin to flavobacterial heparinase was also evaluated. The United States Pharmacopeia (USP) potency of shrimp heparin (SH) was found to be 28 U/mg. SH produced a concentration-dependent prolongation of all of the clotting tests and exhibited marked inhibition of FXa and FIIa. Heparinase treatment resulted in a marked decrease of the anticoagulant effects and neutralized the in vitro anti-IIa actions. However, the anti-Xa activities were only partially neutralized. Protamine sulfate was only partially effective in neutralizing the anticoagulant and antithrombin effects of SH. SH also produced marked prolongation of activated clotting time, which was neutralized by heparinase but not by protamine sulfate. These results suggest that SH is a strong anticoagulant with comparable properties to mammalian heparins and can be used in the development of clinically useful antithrombotic-anticoagulant drugs.
Demir
M
M
Loyola University Medical Center, Maywood, Illinois 60153, USA.
Iqbal
O
O
Dietrich
C P
CP
Hoppensteadt
D A
DA
Ahmad
S
S
Daud
A N
AN
Fareed
J
J
D000818:Animals; D000925:Anticoagulants / Q000302:isolation & purification / Q000378:metabolism / Q000494:pharmacology; D001780:Blood Coagulation Tests; D004305:Dose-Response Relationship, Drug; D015951:Factor Xa / Q000378:metabolism; D065427:Factor Xa Inhibitors; D006493:Heparin / Q000302:isolation & purification / Q000378:metabolism / Q000494:pharmacology*; D019763:Heparin Lyase / Q000378:metabolism; D033561:Penaeidae / Q000737:chemistry*; D011479:Protamines / Q000378:metabolism; D011480:Protease Inhibitors / Q000302:isolation & purification / Q000378:metabolism / Q000494:pharmacology; D011516:Prothrombin / Q000037:antagonists & inhibitors / Q000378:metabolism
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D011479:Protamines; D011480:Protease Inhibitors; D011516:Prothrombin; C025337:Factor IIa; D006493:Heparin; D015951:Factor Xa; D019763:Heparin Lyase